Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Staphylococcus saprophyticus: Which beta-lactam?

Hélène Pailhoriès1, Viviane Cassisa1, Rachel Chenouard1

  • 1Laboratory of Bacteriology, CHU Angers, Angers, France.

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|October 15, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Streptococcus agalactiae bone and joint infection: a multicentre observational study 2014-23.

The Journal of infection·2026
Same author

Clinical and microbiological features in community- and hospital-acquired extended spectrum beta lactamase producing Escherichia coli from urinary tract.

The Journal of hospital infection·2026
Same author

Clinical practice recommendations for the management of hand Infections: A formalized CRIOGO consensus Guideline.

Infectious diseases now·2026
Same author

A disrupted microbial network and an ecological shift towards anaerobes in NTM-infected cystic fibrosis patients.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Spread of extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) in the community living spaces of patients identified as ESBL-E carriers: impact of the housing density in an African context.

Tropical medicine and health·2026
Same author

Well-Being of Student Pharmacists During the Preparation Period of National Pharmacy Internship Competition in France.

American journal of pharmaceutical education·2026

Staphylococcus saprophyticus causes many urinary tract infections (UTIs) treated with ineffective antibiotics. This study highlights the need to consider S. saprophyticus and reassess antibiotic choices like ceftriaxone for UTIs.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Staphylococcus saprophyticus is a common cause of urinary tract infections (UTIs).
  • This bacterium often exhibits resistance to standard empirical UTI treatments.
  • Current treatment strategies may not adequately address S. saprophyticus infections.

Purpose of the Study:

  • To investigate the epidemiology of S. saprophyticus UTIs.
  • To assess the susceptibility of S. saprophyticus to ceftriaxone and amoxicillin-clavulanic acid.
  • To evaluate the appropriateness of empirical antibiotic regimens for S. saprophyticus UTIs.

Main Methods:

  • Analysis of clinical data from S. saprophyticus isolates (methicillin-susceptible S. saprophyticus - MSSS) between November 2014 and July 2016.
Keywords:
Amoxicillin–clavulanic acidBeta-lactamsCeftriaxoneMinimum inhibitory concentrationsStaphylococcus saprophyticus

Related Experiment Videos

  • Measurement of minimum inhibitory concentrations (MICs) for amoxicillin-clavulanic acid and ceftriaxone against MSSS and MSSA strains.

    • Main Results:

    • S. saprophyticus UTIs were linked to cystitis (59.5%) and pyelonephritis (33.3%).
    • Inappropriate antibiotic regimens were administered in 60% of cystitis and 25% of pyelonephritis cases.
    • High ceftriaxone MICs (4 to >32μg/ml) were observed for MSSS strains.

    Conclusions:

    • S. saprophyticus is an under-recognized cause of UTIs, often treated with ineffective empirical antibiotics.
    • High ceftriaxone MICs in S. saprophyticus suggest this antibiotic may not be suitable for treating UTIs caused by this pathogen.
    • Re-evaluation of antibiotic susceptibility and treatment guidelines for S. saprophyticus UTIs is warranted.